Evaxion Biotech A/S (NASDAQ:EVAX) Given New $6.00 Price Target at Lake Street Capital

Evaxion Biotech A/S (NASDAQ:EVAX) had its price target decreased by Lake Street Capital from $35.00 to $6.00 in a research report sent to investors on Tuesday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a report on Monday.

Evaxion Biotech A/S Stock Down 8.0 %

Shares of EVAX opened at $2.75 on Tuesday. The company’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $10.48. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a 1 year low of $2.22 and a 1 year high of $23.70. The stock has a market capitalization of $3.22 million, a PE ratio of -1.90 and a beta of -0.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.